新華健康｜華為與固生堂達成合作 推動中醫藥智慧化轉型
5月13日，廣東固生堂中醫養生健康科技股份有限公司（以下簡稱“固生堂”）與華為技術有限公司（以下簡稱“華為”）在華為東莞松山湖總部舉行合作協議簽署儀式。
據瞭解，雙方此次合作聚焦中醫藥大模型研發、數字基礎設施建設、複合型人才培養、行業生態共建四大核心領域，旨在為中醫藥行業的數智化轉型與智能化升級注入強勁動力，推動中醫藥現代化邁向新高度。
廣東固生堂中醫養生健康科技股份有限公司與華為技術有限公司在華為東莞松山湖總部舉行合作協議簽署儀式
固生堂獨立非執行董事仲偉合表示，此次合作是中醫藥行業數字化轉型進程中的一個重要里程碑。他介紹稱，固生堂作為深耕中醫領域十餘年的連鎖醫療機構，已在全國佈局近百家醫館，累計服務患者超過2000萬人次。但實踐中發現，中醫藥現代化仍面臨醫療資源分佈不均、基層服務能力不足等挑戰。
“華為的生成式人工智能、盤古大模型等技術，為中醫藥智能化轉型提供了關鍵的支撐。” 仲偉合強調，雙方此次合作，讓中醫辨證施治的個體化優勢與大數據分析的精準化能力深度融合，為患者提供更科學更有效的治療方案，推動優質醫療資源下沉，降低患者就醫成本。
華為公共事業軍團COO夏尊表示，中國的數字化、智能化發展已走在世界前列，他希望雙方合作能夠促進技術的傳承與創新，共同推動中醫藥走出去。
簽署儀式上，固生堂中醫連鎖管理集團副總裁鄭項透露，經過一個月的訓練，目前，企業打造的部分中醫AI分身能夠達到名老中醫70%以上的治療能力，預計在兩個月的時間和數據積累之後，能夠達到90%以上。
上海市人大教科文衞委員會主任委員、上海中醫藥大學原校長徐建光出席儀式並在發言中表示，隨着合作成果的逐步落地，中醫藥服務將朝着精準化、個性化、智能化方向加速升級，為全球傳統醫學的現代化發展貢獻獨具特色的中國方案。（記者 劉鴻秀）
來源：經濟參考網
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
